Aerovate Therapeutics: Q2 Earnings Insights
Aerovate Therapeutics (NASDAQ:AVTE) reported its Q2 earnings results on Monday, August 15, 2022 at 09:00 AM.
Here's what investors need to know about the announcement.
Aerovate Therapeutics Q2 EPS $(0.49) Up From $(23.80) YoY
Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.49) per share. This is a 97.94 percent increase over losses of $(23.80) per share from the same period last year.
Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday
Gainers
GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday.
Why Is Infrastructure and Energy Alternatives Higher By Around 29%? 37 Stocks Moving In Monday’s Mid-Day Session
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
Gainers
AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.
Tesla, Coinbase Global And 41 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intelligent Living Application Group Inc. (NASDAQ: ILAG) shares jumped 90.2% to $4.2792 after declining 11% on Friday. The company reported closing of $20.24 million initial public offering.
Carnival Surges Over 12%, Here’s 75 Biggest Movers From Friday
Gainers
USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
55 Biggest Movers From Friday
Gainers
Takung Art Co., Ltd. (NASDAQ: TKAT) surged 61.8% to close at $3.64 on Friday.
38 Stocks Moving In Friday’s Mid-Day Session
Gainers
Manning & Napier, Inc. (NYSE: MN) jumped 40.7% to $12.82 after the company reported it will be acquired by Callodine Group and will go private at $12.85 per share.
BTIG Initiates Coverage On Aerovate Therapeutics with Buy Rating, Announces Price Target of $24
BTIG initiates coverage on Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and announces Price Target of $24.